Indegene Partners with Microsoft to Boost GenAI in Life Science Firms

Indegene, a life sciences commercialization firm, has announced a strategic partnership with Microsoft to help global life sciences firms accelerate the adoption of purpose-built, enterprise-grade Generative AI (GenAI) services, resulting in faster innovation at scale.

The two businesses will collaborate to develop medical and technical resources in order to co-create generative AI services and processes spanning commercial, medical, regulatory, and clinical roles.   “GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations throughout the value chain. Using GenAI, we’re closely working with many of our clients to solve specific business problems, with nearly 50 real-world use cases already in an advanced pilot stage,” said Tarun Mathur, CTO, Indegene.   “We remain focused on helping our clients harness the potential of GenAI with targeted solutions to address some of their most pressing operational challenges and make their business future-ready.”   Alok Lall, chief operating officer, Microsoft India?& South Asia, said, “Generative AI is profoundly shaping every industry, including life sciences, by offering unprecedented avenues for healthcare technology advancements.

According to a Microsoft-commissioned survey done by IDC, 79% of healthcare firms have adopted AI. “This demonstrates that the tangible business value of this transformation is indisputable. By seamlessly integrating Indegene's domain knowledge with Microsoft Azure OpenAI Service and Microsoft Copilot, we stand at the forefront of advancing generative AI within the life sciences sector. This collaborative effort empowers life sciences companies to fully harness AI's capabilities, fostering innovation and scalability within the industry.”